Pfizer Inc. (NYSE:PFE) Holdings Lowered by Lynch & Associates IN

Lynch & Associates IN cut its stake in Pfizer Inc. (NYSE:PFE) by 28.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,031 shares of the biopharmaceutical company’s stock after selling 35,363 shares during the period. Lynch & Associates IN’s holdings in Pfizer were worth $2,498,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. GoalVest Advisory LLC raised its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. Creekmur Asset Management LLC bought a new stake in Pfizer in the fourth quarter worth about $32,000. VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer during the 4th quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $37,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.8 %

Pfizer stock traded up $0.23 during trading hours on Thursday, hitting $27.64. The company had a trading volume of 10,376,085 shares, compared to its average volume of 41,067,395. The firm’s fifty day moving average is $27.61 and its 200-day moving average is $27.73. The firm has a market capitalization of $156.62 billion, a P/E ratio of -460.76, a price-to-earnings-growth ratio of 1.08 and a beta of 0.70. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $39.24. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.23 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.08%. Pfizer’s dividend payout ratio is -2,799.53%.

Analysts Set New Price Targets

Several analysts recently commented on PFE shares. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $35.86.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.